Prostate-specific membrane antigen (PSMA) is a protein found in small amounts in your prostate gland. When you have prostate cancer, you have many times more PSMA than normal. This makes PSMA a ...

One new treatment uses radiopharmaceuticals to zero in on cancer cells to destroy them. The therapy, called 177 Lu-PSMA-617 (Pluvicto ®), includes a molecule that selectively seeks out and attaches to ...

Surgery patients staged with PSMA-PET appear to have a lower risk of early BCR than those staged with conventional imaging. Early oncologic outcomes after radical prostatectomy (RP) for very high ...

What Is a PSMA PET Scan? A PSMA PET scan, or prostate-specific membrane antigen positron emission tomography scan, is a recently developed imaging test used for people with prostate cancer.

Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177 Lu)–PSMA-617 is a radioligand therapy that delivers beta ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...

Gozellix, a PSMA-PET imaging agent, is FDA-approved for detecting prostate cancer metastasis and recurrence, enhancing access to advanced imaging. The approval is supported by data from the PSMA-PreRP ...

Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 ...

The cost of making a Phycoerythrin conjugated tetramer is $800. The most expensive reagents are the biotin ligase (BirA from Avidity, LLC) and the PE-conjugated streptavidin (Prozyme). On occasion, it ...

MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET 1 imaging agent ...